A year into SPAC merger, Gemini restructures pipeline with 20% of staff, leadership on the chopping block
Gemini Therapeutics jumped to Nasdaq in a SPAC deal about a year ago, but on Tuesday announced a significant change in direction.
The biotech will undergo a corporate restructuring to focus on its clinical stage candidates, dropping all research and discovery programs and laying off 20% of its staff, it said in a Tuesday morning release. Gemini will attempt to reposition itself to better fund a pivotal study for its geographic atrophy program, dubbed GEM103.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.